0

“Buzz on the Street” Show: Amarantus Bioscience (OTC: AMBS) Sublicense to Emerald Organic Products

Amarantus Bioscience Holdings, Inc. (OTC: AMBS), a biotechnology holding company pursuing proprietary therapeutics and diagnostics through its subsidiaries, today announced that it has completed an exclusive worldwide sublicense agreement for development rights of Cutanogen Corporation’s and MANF Therapeutics, Inc.’s pipelines to Emerald Organic Products (OTC: EMOR, or “Emerald”), a diversified cannabidiol (“CBD”)-focused health sciences company. […]

0

“Buzz on the Street” Show: Amarantus Bioscience (OTC: AMBS) Eltoprazine & CBD to Treat Parkinson’s

Amarantus Bioscience Holdings, Inc. (OTC: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that subsidiary Elto Pharma, Inc. has received a notice of allowance from the European Patent Office (EPO) covering the use of eltoprazine and eltoprazine […]

0

“Buzz on the Street” Show: Amarantus Bioscience (OTC: AMBS) Patent to Treat Retinal Disorders

Amarantus Bioscience Holdings, Inc. (OTC: AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that subsidiary MANF Therapeutics has been issued a Chinese patent covering the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) and/or cerebral dopamine neurotrophic factor (CDNF) for the […]